Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

Illumina's technology is extremely well-established, and serves as the backbone for most large-scale genome sequencing projects currently underway (including the majority of the samples sequenced ...

Illumina, Inc. has unveiled a service program to provide high-quality personal genome sequencing for consumers. This is the first service to offer complete coverage of the human genome sequence for ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Under the proposed agreement with Regeneron, the Tarrytown, New York, drugmaker will acquire 23andMe's assets, including its personal genome service and total health and research services.

Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS), Total Health, and Research Services business lines, together with its Biobank and associated assets.

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), an American biotechnology company, on Monday announced that it planned to acquire 23andMe Holding Co.'s Personal Genome Service, Total Health ...

The transaction, expected to close in the third quarter of 2025, includes 23andMe’s core Personal Genome Service, Total Health and Research Services, and a vast biobank of customer genetic data ...

23andMe filed for bankruptcy protection in March this year. Regeneron emerged as the successful bidder in the bankruptcy auction for 23andMe assets and plans to acquire its Personal Genome Service ...

This includes the company’s Personal Genome Service (PGS) and Total Health and Research Services business lines, but not the Lemonaid Health subsidiary. Lemonaid Health, a telehealth company ...